CFD'er er komplekse instrumenter, og der er stor risiko for at miste penge hurtigt på grund af gearing. 84% af individuelle investorer taber penge, når de handler CFD'er med denne udbyder. Du bør overveje, om du forstår, hvordan CFD'er virker, og om du har råd til at løbe en høj risiko for at miste dine penge.

Scan to Download iOS&Android APP

Handel Calcimedica Inc - CALC CFD

5.5507
1.05%
  • Opsummering
  • Historisk Data
  • Begivenheder
  • Resultatopgørelse
  • Saldo
  • Cash flow
  • Ejerskab
Handelsbetingelser
Spænd 0.4586
Long position, gebyr natten over

Long position overnight fee


Margin. Your investment $1,000.00
Gebyr for natten over -0.024068 %
Charges from borrowed part ($-0.96)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Gå til platform
-0.024068%
Short position, gebyr natten over

Short position overnight fee


Margin. Your investment $1,000.00
Gebyr for natten over 0.001846 %
Charges from borrowed part ($0.07)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Gå til platform
0.001846%
Gebyr natten over, tid 21:00 (UTC)
Min. handlet mængde 0.001
Valuta USD
Margen 20%
Aktiebørs United States of America
Kommission på handel 0%

*Information provided by Capital.com

Nøglestatistikker
Tidligere luk* 5.4929
Åben* 5.4688
1-Års Ændring* 317.47%
Dagens Spænd* 5.4688 - 5.7853
52-Ugers Spænd 4.88-20.30
Gennemsnitlig Volumen (10 dage) 22.09K
Gennemsnitlig Volumen (3 måneder) 103.52K
Market Cap 8.89M
P/E-forhold -100.00K
Udestående aktier 5.52M
Omsætning N/A
EPS -23.21
Dividend (Udbytte %) N/A
Beta -100.00K
Næste indtjeningsopgørelse May 8, 2023

Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Luk Change Change (%) Åben High Low
Mar 24, 2023 5.5507 0.0832 1.52% 5.4675 5.7853 5.4675
Mar 23, 2023 5.4929 0.1525 2.86% 5.3404 5.8023 5.3404
Mar 22, 2023 5.5768 0.2301 4.30% 5.3467 6.5507 5.0805
Mar 21, 2023 6.0468 1.2311 25.56% 4.8157 6.1436 4.7284
Mar 20, 2023 5.3451 -0.6469 -10.80% 5.9920 5.9920 5.0602
Mar 17, 2023 0.4280 -0.0478 -10.05% 0.4758 0.4763 0.4273
Mar 16, 2023 0.4761 -0.0195 -3.93% 0.4956 0.4958 0.4580
Mar 15, 2023 0.4937 0.0277 5.94% 0.4660 0.4969 0.4660
Mar 14, 2023 0.4762 -0.0145 -2.95% 0.4907 0.4957 0.4737
Mar 13, 2023 0.4960 -0.0093 -1.84% 0.5053 0.5151 0.4859
Mar 10, 2023 0.5041 0.0008 0.16% 0.5033 0.5120 0.4857
Mar 9, 2023 0.5346 -0.0034 -0.63% 0.5380 0.5637 0.5164
Mar 8, 2023 0.5638 0.0408 7.80% 0.5230 0.5647 0.5230
Mar 7, 2023 0.5637 0.0395 7.54% 0.5242 0.5823 0.5242
Mar 6, 2023 0.5556 -0.0273 -4.68% 0.5829 0.5829 0.5537
Mar 3, 2023 0.5476 0.0429 8.50% 0.5047 0.5588 0.5047
Mar 2, 2023 0.5345 0.0292 5.78% 0.5053 0.5347 0.5053
Mar 1, 2023 0.5390 0.0045 0.84% 0.5345 0.5832 0.5339
Feb 28, 2023 0.5285 -0.0056 -1.05% 0.5341 0.5347 0.5179
Feb 27, 2023 0.5536 -0.0004 -0.07% 0.5540 0.5543 0.5343

Calcimedica Inc Events

Tid (UTC) (UTC) Land Begivenhed
No events scheduled
Se alle begivenheder
  • Årlig
  • Pr kvartal
2021 2020 2019 2018
Total omsætning 0 0 0 0
Totale Driftsudgifter 35.947 29.832 37.502 28.57
Salgs/Generelle/Admin. Udgifter, Total 17.044 8.87 6.922 5.599
Forskning & Udvikling 18.903 20.962 30.58 22.971
Driftsindtægter -35.947 -29.832 -37.502 -28.57
Renteindkomst (Udgift), Netto Ikke-Drift 0.126 0.143 0.393 0.192
Andre, Netto 0 2.158 0.072 0
Netto Indkomst Før Skat -35.821 -27.531 -37.037 -28.378
Netto Indkomst Efter Skat -35.821 -27.531 -37.037 -28.378
Netto Indkomst Før Ekstra Ting -35.821 -27.531 -37.037 -28.378
Netto Indkomst -35.821 -27.531 -37.037 -28.378
Total Adjustments to Net Income 0 -7.189 -7.055 -4.317
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -35.821 -34.72 -44.092 -32.695
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -35.821 -34.72 -44.092 -32.695
Fortyndet Netto Indkomst -35.821 -34.72 -44.092 -32.695
Fortyndet Vægtet Gennemsnit Aktier 21.1993 21.044 19.1556 19.1556
Fortyndet EPS Uden Ekstraordinære Ting -1.68973 -1.64988 -2.30178 -1.70681
Dividends per Share - Common Stock Primary Issue 0 0
Fortyndet Normaliseret EPS -1.68973 -1.64988 -2.30178 -1.70681
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total omsætning 0 0 0 0 0
Totale Driftsudgifter 10.184 8.701 8.017 7.741 11.488
Salgs/Generelle/Admin. Udgifter, Total 4.127 4.433 3.996 3.575 5.04
Forskning & Udvikling 6.057 4.268 4.021 4.166 6.448
Driftsindtægter -10.184 -8.701 -8.017 -7.741 -11.488
Renteindkomst (Udgift), Netto Ikke-Drift 0.035 0.026 0.028 0.033 0.039
Andre, Netto 0 0 0 0
Netto Indkomst Før Skat -10.149 -8.675 -7.989 -7.708 -11.449
Netto Indkomst Efter Skat -10.149 -8.675 -7.989 -7.708 -11.449
Netto Indkomst Før Ekstra Ting -10.149 -8.675 -7.989 -7.708 -11.449
Netto Indkomst -10.149 -8.675 -7.989 -7.708 -11.449
Total Adjustments to Net Income 0 0 0 0
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -10.149 -8.675 -7.989 -7.708 -11.449
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -10.149 -8.675 -7.989 -7.708 -11.449
Fortyndet Netto Indkomst -10.149 -8.675 -7.989 -7.708 -11.449
Fortyndet Vægtet Gennemsnit Aktier 21.3578 21.3376 21.2875 21.1487 21.0204
Fortyndet EPS Uden Ekstraordinære Ting -0.47519 -0.40656 -0.37529 -0.36447 -0.54466
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Fortyndet Normaliseret EPS -0.47519 -0.40656 -0.37529 -0.36447 -0.54466
  • Årlig
  • Pr kvartal
2021 2020 2019 2018
Totale Nuværende Aktiver 67.078 99.24 36.271 13.445
Likvider og Kortsigtede Investeringer 63.67 95.033 35.956 12.834
Likvider & Lignende 13.364 33.418 15.87 12.834
Kortsigtede Investeringer 50.306 61.615 20.086 0
Prepaid Expenses 2.034 4.207 0.315 0.611
Total Assets 69.088 101.794 40.66 17.813
Property/Plant/Equipment, Total - Net 1.981 1.946 1.975 1.515
Property/Plant/Equipment, Total - Gross 3.634 3.08 2.714 1.958
Accumulated Depreciation, Total -1.653 -1.134 -0.739 -0.443
Other Long Term Assets, Total 0.029 0.608 2.414 2.853
Total Current Liabilities 4.057 6.997 12.251 5.794
Accounts Payable 0.527 2.513 4.636 2.523
Accrued Expenses 2.582 3.658 4.377 2.924
Notes Payable/Short Term Debt 0 0 0 0
Other Current Liabilities, Total 0.948 0.826 3.238 0.347
Total Liabilities 4.065 7.008 12.251 5.794
Total Long Term Debt 0 0 0 0
Total Equity 65.023 94.786 28.409 12.019
Preferred Stock - Non Redeemable, Net 0 0 131.363 78.811
Common Stock 0.002 0.002 0 0
Additional Paid-In Capital 234.225 228.155 2.879 2.007
Retained Earnings (Accumulated Deficit) -169.188 -133.367 -105.836 -68.799
Unrealized Gain (Loss) -0.016 -0.004 0.003 0
Total Liabilities & Shareholders’ Equity 69.088 101.794 40.66 17.813
Total Common Shares Outstanding 21.3578 20.9793 19.1556 19.1556
Other Liabilities, Total 0.008 0.011
Total Preferred Shares Outstanding 0
Totale Tilgodehavender, Netto 0.021
Other Current Assets, Total 1.353
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Totale Nuværende Aktiver 58.222 67.078 74.496 76.051 88.821
Likvider og Kortsigtede Investeringer 55.28 63.67 72.554 73.586 85.688
Likvider & Lignende 8.36 13.364 11.452 7.864 10.589
Kortsigtede Investeringer 46.92 50.306 61.102 65.722 75.099
Prepaid Expenses 2.942 3.408 1.942 2.465 3.133
Total Assets 60.586 69.088 76.638 82.821 90.852
Property/Plant/Equipment, Total - Net 2.335 1.981 2.113 2.006 2.002
Other Long Term Assets, Total 0.029 0.029 0.029 0.136 0.029
Total Current Liabilities 4.228 4.057 4.49 4.141 6.278
Accounts Payable 0.541 0.527 2.066 2.101 1.956
Accrued Expenses 2.216 2.582 1.729 1.543 3.378
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 1.471 0.948 0.695 0.497 0.944
Total Liabilities 4.33 4.065 4.502 4.154 6.29
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0.102 0.008 0.012 0.013 0.012
Total Equity 56.256 65.023 72.136 78.667 84.562
Common Stock 0.002 0.002 0.002 0.002 0.002
Additional Paid-In Capital 235.767 234.225 232.641 231.183 229.376
Retained Earnings (Accumulated Deficit) -179.337 -169.188 -160.513 -152.524 -144.816
Unrealized Gain (Loss) -0.176 -0.016 0.006 0.006 0
Total Liabilities & Shareholders’ Equity 60.586 69.088 76.638 82.821 90.852
Total Common Shares Outstanding 21.3578 21.3578 21.3166 21.2847 21.0559
Long Term Investments 4.628
Preferred Stock - Non Redeemable, Net 0 0
  • Årlig
  • Pr kvartal
2021 2020 2019 2018
Netto indkomst/Startlinje -35.821 -27.531 -37.037 -28.378
Likvider Fra Driftsaktiviteter -31.5 -32.064 -31.215 -28.216
Likvider Fra Driftsaktiviteter 0.519 0.395 0.303 0.175
Ikke-Likvide Ting 5.433 -0.369 0.598 0.366
Ændringer i Driftskapital -1.631 -4.559 4.921 -0.379
Likvider fra Investeringsaktiviteter 10.751 -42.56 -20.62 -1.461
Kapitaludgifter -0.488 -1.023 -0.605 -1.461
Andre Investerings-Cash-Flow-Ting, Total 11.239 -41.537 -20.015 0
Likvider fra Financieringsaktiviteter 0.695 92.172 54.871 42.019
Financiering af Cash-Flow-Ting 0 -4.16 -0.045 0
Udstedelse (Pensionering) af Aktier, Netto 0.695 96.332 54.916 42.019
Netto Ændring i Likviditet -20.054 17.548 3.036 12.342
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -10.149 -35.821 -27.146 -19.157 -11.449
Cash From Operating Activities -6.524 -31.5 -22.545 -17.045 -9.264
Cash From Operating Activities 0.122 0.519 0.383 0.247 0.118
Non-Cash Items 3.81 5.433 3.946 2.508 1.169
Changes in Working Capital -0.307 -1.631 0.272 -0.643 0.898
Cash From Investing Activities 1.52 10.751 -0.035 -9.096 -13.657
Capital Expenditures 0 -0.488 -0.484 -0.304 -0.136
Other Investing Cash Flow Items, Total 1.52 11.239 0.449 -8.792 -13.521
Cash From Financing Activities 0 0.695 0.614 0.587 0.092
Financing Cash Flow Items 0 0 0 0
Issuance (Retirement) of Stock, Net 0 0.695 0.614 0.587 0.092
Net Change in Cash -5.004 -20.054 -21.966 -25.554 -22.829
Investornavn Investortype Procent udestående Aktiebeholdning Aktieændring Beholdningsdato IOmsætningsscore
Deerfield Management Company, L.P. Hedge Fund 6.8373 377265 0 2022-12-31 MED
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 5.3895 297380 -2 2023-03-22 LOW
BML Capital Management LLC Investment Advisor 1.6 88282 0 2022-12-31 MED
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 0.5436 29995 13 2022-12-31 LOW
Guerard (Frederic) Individual Investor 0.4451 24562 16153 2023-03-03 HIGH
CVF 2018, LLC Corporation 0.3531 19485 -56817 2021-12-31
First Manhattan Co. LLC Investment Advisor 0.3512 19381 -1476 2022-12-31 LOW
Renaissance Technologies LLC Hedge Fund 0.2019 11143 -3178 2022-12-31 HIGH
Breuil (Robert S) Individual Investor 0.1861 10266 5360 2023-03-14 HIGH
Zamiri (Parisa) Individual Investor 0.1495 8247 5554 2023-03-03 HIGH
BNY Mellon Asset Management Investment Advisor 0.1297 7159 -54 2022-12-31 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.0857 4730 -12 2022-12-31 LOW
Johnson & Johnson Innovation-JJDC, Inc. Venture Capital 0.0641 3539 0 2022-12-31 LOW
Susquehanna International Group, LLP Investment Advisor 0.0581 3204 -1313 2022-12-31 MED
Hatteras Venture Partners Venture Capital 0.0557 3076 -111584 2021-12-31 LOW
Bridgeway Capital Management, LLC Investment Advisor 0.0542 2993 -1578 2022-12-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.0454 2505 0 2022-12-31 LOW
Advisor Group, Inc Investment Advisor 0.0246 1357 0 2022-12-31 LOW
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.0208 1150 0 2022-12-31 LOW
Morgan Stanley & Co. LLC Research Firm 0.0154 851 0 2022-12-31 MED

Hvorfor vælge Capital.com? Vores tal taler for sig selv.

Capital.com Group

500K+

Handlende

92K+

Månedlkige, aktive klienter

$53M+

Månedlig investeringsvolumen

$30M+

Hævet hver måned

Handelslommeregner

Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).

Handelskurtage
0
  • 1:1
Gearing
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben

Luk

Short Long

Graybug Vision, Inc. Company profile

Om Graybug Vision, Inc.

Graybug Vision, Inc. er en biofarmaceutisk virksomhed i den kliniske fase, der fokuserer på at udvikle transformative lægemidler til behandling af sygdomme i nethinden og synsnerven. Selskabets førende produktkandidat, GB-102, er en intravitreal injektion af en mikropartikeldepotformulering af sunitinib, en hæmmer af neovaskulær vækst og permeabilitet, som er årsager til nethindesygdomme. Virksomheden er ved at udvikle GB-102 som en intravitreal injektion én gang hver sjette måned til behandling af våd aldersrelateret makuladegeneration eller våd (AMD) og diabetisk makulaødem (DME). Virksomheden anvender også sine teknologier til at udvikle GB-103, en formulering af GB-102, der anvendes én gang om året, til behandling af diabetisk retinopati (DR), samt GB-401, en intravitrealt injicerbar depotformulering af et prodrug af et beta-adrenergt blokerende middel med et doseringsskema på én gang hver sjette måned eller længere til behandling af primær åbenvinklet glaukom (POAG).

Industry: Bio Therapeutic Drugs

505 Coast Boulevard South
Suite 307
LA JOLLA
CALIFORNIA 92037
US

Resultatopgørelse

  • Annual
  • Quarterly

Folk ser også

Gold

1,978.85 Price
-0.760% 1D Chg, %
Long position, gebyr natten over -0.0179%
Short position, gebyr natten over 0.0097%
Gebyr natten over, tid 21:00 (UTC)
Spænd 0.30

XRP/USD

0.45 Price
+6.070% 1D Chg, %
Long position, gebyr natten over -0.0753%
Short position, gebyr natten over 0.0069%
Gebyr natten over, tid 21:00 (UTC)
Spænd 0.00435

US100

12,798.80 Price
+0.420% 1D Chg, %
Long position, gebyr natten over -0.0241%
Short position, gebyr natten over 0.0018%
Gebyr natten over, tid 21:00 (UTC)
Spænd 3.0

Oil - Crude

69.28 Price
-0.330% 1D Chg, %
Long position, gebyr natten over -0.0194%
Short position, gebyr natten over -0.0025%
Gebyr natten over, tid 21:00 (UTC)
Spænd 0.03

Leder du stadig efter en mægler, du kan stole på?

Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com

1. Opret og bekræft din konto 2. Lav en inddbetaling 3. Find din handel